NPI: 1477517738 · ARLINGTON, VA 22203 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 04/13/2006
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 04/13/2006 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 19,884 | $338K |
| 2019 | 19,797 | $558K |
| 2020 | 17,538 | $581K |
| 2021 | 19,733 | $562K |
| 2022 | 15,151 | $515K |
| 2023 | 4,538 | $322K |
| 2024 | 4,677 | $377K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90935 | Hemodialysis procedure with single evaluation by a physician | 12,636 | 1,006 | $1.89M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 22,371 | 1,419 | $1.06M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 29,133 | 1,537 | $207K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 642 | 345 | $55K |
| J1756 | Injection, iron sucrose, 1 mg | 6,093 | 1,357 | $32K |
| J1270 | Injection, doxercalciferol, 1 mcg | 19,386 | 1,383 | $6K |
| A4657 | Syringe, with or without needle, each | 4,123 | 1,058 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | 924 | 73 | $792.30 |
| 83970 | 1,093 | 665 | $40.59 | |
| 82728 | 1,026 | 673 | $34.92 | |
| 83550 | 813 | 523 | $32.96 | |
| 83540 | 1,065 | 700 | $32.05 | |
| 85041 | 951 | 644 | $0.72 | |
| 85048 | 915 | 621 | $0.61 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 147 | 75 | $0.00 |